Angiozyme

Angiozyme is an anti-angiogenic ribozyme.[1] It is largely being studied in the treatment of kidney cancer. It may prevent the growth of blood vessels from surrounding tissue to the tumor, i.e., angiogeneis. It belongs to the families of drugs called VEGF receptor and angiogenesis inhibitors. Preliminary tests have demonstrated that Angiogenesis has no significant side effects.[2] the Also called RPI.4610

References

"Ribozyme Pharmaceuticals Going Into Clinical Trials with Herzyme, Ribozyme Directed Against HER-2". www.bioprocessonline.com. Retrieved 2017-09-21.
Weng, D. E.; Usman, N. (March 2001). "Angiozyme: a novel angiogenesis inhibitor". Current Oncology Reports. 3 (2): 141–146. ISSN 1523-3790. PMID 11177746.

External links

Angiozyme entry in the public domain NCI Dictionary of Cancer Terms

This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Ribozyme Pharmaceuticals Going Into Clinical Trials with Herzyme, Ribozyme Directed Against HER-2". www.bioprocessonline.com. Retrieved 2017-09-21.

[2] Weng, D. E.; Usman, N. (March 2001). "Angiozyme: a novel angiogenesis inhibitor". Current Oncology Reports. 3 (2): 141–146. ISSN 1523-3790. PMID 11177746.